Endothelial lipase and reverse cholesterol transport in type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 1, Issue 3, 2010, Pages 111-116

  Shiu, Sammy W M ^a   Zhou, Huali ^a   Wong, Ying ^a   Tan, Kathryn C B ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cholesterol efflux; Endothelial lipase; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIAL LIPASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADULT; AGE; ANIMAL CELL; ARTERIAL STIFFNESS; ARTICLE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CULTURE TECHNIQUE; FEMALE; FEMORAL ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; RAT; REVERSE CHOLESTEROL TRANSPORT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 79953752962     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00016.x     Document Type: Article

References (34)

1. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 2002; 43: 921-929.
2. Jaye M, Lynch KJ, Krawiec J, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999; 21: 424-428.
3. Ishida T, Choi S, Kundu RK, et al. Endothelial lipase is a major determinant of HDL level. J Clin Invest 2003; 111: 347-355.
4. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 2003; 111: 357-362.
5. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A 2003; 100: 2748-2753.
6. Badellino K, Wolfe M, Reilly M, Rader D. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006; 3: e22.
7. Paradis ME, Badellino KO, Rader DJ, et al. Visceral adiposity and endothelial lipase. J Clin Endocrinol Metab 2006; 91: 3538-3543.
8. Paradis ME, Badellino KO, Rader DJ, et al. Endothelial lipase is associated with inflammation in humans. J Lipid Res 2006; 47: 2808-2813.
9. Shiu SW, Tan KC, Huang Y, Wong Y. Type 2 diabetes mellitus and endothelial lipase. Atherosclerosis 2008; 198: 441-447.
10. Azumi H, Hirata K, Ishida T, et al. Immunohistochemical localization of endothelial cell-derived lipase in atherosclerotic human coronary arteries. Cardiovasc Res 2003; 58: 647-654.
11. Strauss JG, Zimmermann R, Hrzenjak A, et al. Endothelial cell-derived lipase mediates uptake and binding of high-density lipoprotein (HDL) particles and the selective uptake of HDL-associated cholesterol esters independent of its enzymic activity. Biochem J 2002; 368: 69-79.
12. Gauster M, Oskolkova OV, Innerlohinger J, Glatter O, Knip-ping G, Frank S. Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux. Biochem J 2004; 382: 75-82.
13. Qiu G, Hill JS. Endothelial lipase promotes apolipoprotein AI-mediated cholesterol efflux in THP-1 macrophages. Arterioscler Thromb Vasc Biol 2009; 29: 84-91.
14. Yancey PG, Kawashiri MA, Moore R, et al. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 2004; 45: 337-346.
15. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001; 32: 454-460.
16. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-2090.
17. Zhou H, Tan KC, Shiu SW, Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab Res Rev 2008; 24: 617-623.
18. Catalano G, Julia Z, Frisdal E, et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009; 29: 268-275.
19. von Eckardstein A, Nofer JR, Assmann G. High density lipo-proteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27.
20. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40: 781-796.
21. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54: 788-800.
22. Pajunen P, Syvänne M, Castro G, Nieminen MS, Taskinen MR. Cholesterol efflux capacity in vitro predicts the severity and extent of coronary artery disease in patients with and without type 2 diabetes. Scand Cardiovasc J 2001; 35: 96-100.
23. Mikkola TS, Anthony MS, Clarkson TB, St Clair RW. Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis 2003; 170: 31-38.
24. Syvanne M, Castro G, Dengremont C, et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996; 127: 245-253.
25. Fuki IV, Blanchard N, Jin W, et al. Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J Biol Chem 2003; 278: 34331-34338.
26. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-1145.
27. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006; 1084: 89-117.
28. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase is increased in vivo by inflammation in humans. Circulation 2008; 117: 678-685.
29. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol 2002; 22: 1213-1218.
30. Ansell BJ, Fonarow GC, Navab M, Fogelman AM. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep 2007; 9: 57-63.
31. Khovidhunkit W, Shigenaga JK, Moser AH, Feingold KR, Grun-feld C. Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J Lipid Res 2001; 42: 967-975.
32. Levels JH, Pajkrt D, Schultz M, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007; 1771: 1429-1438.
33. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 25(Suppl. 1): IV31-IV46.
34. Farrar DJ, Green HD, Bond MG, Wagner WD, Gobbeé RA. Aortic pulse wave velocity, elasticity, and composition in a nonhuman primate model of atherosclerosis. Circ Res 1978; 43: 52-62.